MetLife (MET) Aandelenoverzicht
MetLife, Inc., een financiële dienstverlener, biedt wereldwijd diensten aan op het gebied van verzekeringen, lijfrentes, employee benefits en vermogensbeheer. Meer informatie
| Sneeuwvlok Score | |
|---|---|
| Waardering | 2/6 |
| Toekomstige groei | 1/6 |
| Prestaties in het verleden | 1/6 |
| Financiële gezondheid | 3/6 |
| Dividenden | 5/6 |
MET Community Fair Values
Create NarrativeSee what 49 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
MetLife, Inc. Concurrenten
Prijsgeschiedenis en prestaties
| Historische aandelenkoersen | |
|---|---|
| Huidige aandelenkoers | US$93.46 |
| 52 Week Hoogtepunt | US$100.93 |
| 52 Week Laag | US$67.33 |
| Bèta | 0.76 |
| 1 maand verandering | 0.096% |
| 3 maanden verandering | 11.18% |
| 1 Jaar Verandering | 17.95% |
| 3 jaar verandering | 50.09% |
| 5 jaar verandering | 51.25% |
| Verandering sinds IPO | 533.63% |
Recent nieuws en updates
Narratiefupdate • Aug 08
MET: Buybacks And Settlement Features Will Shape A Measured Future Risk Reward Balance
Analysts have lifted their price target on MetLife to $100.44 from $97.75, citing updated assumptions for fair value, discount rate, revenue growth, profit margin, and future P/E. These changes collectively support a slightly higher valuation framework.Seeking Alpha • Aug 06
MetLife's Q2 Earnings Beat Reaffirms The Buy Case As Organic Growth Stands Out
Summary MetLife, Inc. is reaffirmed as a Buy, with quality fundamentals, strong organic growth, and a resilient dividend profile supporting continued bullish momentum. MET's diversified business model, including investment management and group benefits, drives organic growth across multiple segments despite modest profit margin expansion. The balance sheet boasts A-level credit ratings and modest leverage, but significant fixed-income exposure introduces interest rate risk, warranting ongoing monitoring. MET is fairly valued with upside potential into 2026, outperforming the S&P 500 recently, though it is vulnerable to broad market downturns impacting financial stocks. Read the full article on Seeking AlphaRecent updates
Narratiefupdate • Aug 08
MET: Buybacks And Settlement Features Will Shape A Measured Future Risk Reward Balance
Analysts have lifted their price target on MetLife to $100.44 from $97.75, citing updated assumptions for fair value, discount rate, revenue growth, profit margin, and future P/E. These changes collectively support a slightly higher valuation framework.Seeking Alpha • Aug 06
MetLife's Q2 Earnings Beat Reaffirms The Buy Case As Organic Growth Stands Out
Summary MetLife, Inc. is reaffirmed as a Buy, with quality fundamentals, strong organic growth, and a resilient dividend profile supporting continued bullish momentum. MET's diversified business model, including investment management and group benefits, drives organic growth across multiple segments despite modest profit margin expansion. The balance sheet boasts A-level credit ratings and modest leverage, but significant fixed-income exposure introduces interest rate risk, warranting ongoing monitoring. MET is fairly valued with upside potential into 2026, outperforming the S&P 500 recently, though it is vulnerable to broad market downturns impacting financial stocks. Read the full article on Seeking AlphaNarratiefupdate • Jul 25
MET: Capital Returns And Flexible Settlement Solutions Will Shape Future Risk Reward Balance
Analysts have raised their price target for MetLife to $97.75 from $95.31, reflecting small revisions to fair value estimates, discount rate, revenue growth, profit margin, and future P/E assumptions. What’s in the News for MetLife MetLife introduced the Non-Qualified Assignment Flex Agreement, a deferred payment solution that uses a funding agreement rather than an annuity to structure non-physical injury settlements with flexible start dates, lump sums, and customized payment schedules.Narratiefupdate • Jul 11
MET: Capital Returns And Flexible Settlement Solutions Will Shape Future Risk Reward Balance
MetLife's analyst price target has been revised from $92.80 to $95.31. Analysts attribute this change to updated assumptions for fair value, discount rate, revenue growth, profit margin, and future P/E.Analyse-artikel • Jun 17
MetLife (MET) Stock Could Be 47% Below Fair Value After New Settlement Product
MetLife’s new deferred payment solution puts product design in focus MetLife (MET) recently introduced the Non-Qualified Assignment Flex Agreement, or NQA-FA, a deferred payment solution that gives attorneys and brokers more control over the timing and structure of non-physical injury settlements. The NQA-FA uses a funding agreement rather than an annuity and supports features such as deferred start dates, lump sums and customized payment schedules, potentially broadening how MetLife stock...Narratiefupdate • Jun 09
MET: Capital Returns And Product Flexibility Will Shape Future Risk Reward Balance
Analysts have raised their price target on MetLife to $92.80 from $89.31, citing updated assumptions around fair value, discount rate, revenue growth, profit margin, and future P/E estimates. What's in the News MetLife reported Q1 2026 adjusted earnings growth of 18% year over year, with broad top line growth across all operating segments and resilient margins, supported by expanding businesses in Asia, Latin America, Group Benefits, and Retirement and Income Solutions.Narratiefupdate • May 03
MET: Share Repurchases And Dividend Increases Will Support Future Upside Potential
Analysts have slightly adjusted their fair value estimate for MetLife, nudging the implied price target from about $89.06 to $89.31. This reflects modest tweaks to assumptions around the discount rate, long term revenue growth, profit margin and future P/E multiples.Narratiefupdate • Apr 17
MET: Share Repurchases Following Index Exit Will Support Future Upside Potential
Analysts have slightly reduced their MetLife fair value estimate to $89.06 from $90.50, reflecting minor adjustments to assumptions for the discount rate, revenue growth, profit margin, and future P/E ratio that refine their outlook for the shares. What's in the News MetLife has been dropped from the S&P 100 index, which may influence how some index funds and benchmarks gain exposure to the stock (Key Developments).Narratiefupdate • Apr 01
MET: Share Repurchases And Index Exit Will Shape Future Upside Potential
Analysts have trimmed their average MetLife price target slightly to $90.50 from $90.73, citing updated views on revenue growth, profit margins, and future P/E assumptions. What's in the News MetLife, Inc.Narratiefupdate • Mar 18
MET: Share Repurchases Will Support Future Upside Potential
Analysts have slightly adjusted their price target for MetLife to $90.73 from $90.93, reflecting updated views on discount rates, revenue growth, profit margins, and future price-to-earnings (P/E) assumptions. What's in the News MetLife reported that from October 1, 2025 to January 31, 2026 it repurchased 7,608,263 shares, representing 1.15% of shares, for a total of US$600 million under its current buyback program (Key Developments).Narratiefupdate • Mar 04
MET: Buybacks And Retirement Income Agreements Will Drive Future Upside
Analysts have trimmed their price target on MetLife to about $90.93 from roughly $92.93. This reflects updated views on slightly lower expected revenue growth, a modestly softer profit margin, a higher discount rate, and a largely unchanged future P/E assumption.Narratiefupdate • Dec 16
MET: Retirement Income Agreements Will Drive Future Upside In Earnings Power
Analysts have marginally reduced their price target on MetLife to approximately 92.93 dollars from 93 dollars, citing a slightly higher assumed discount rate. This more than offsets modest improvements in forecast profit margins and valuation multiples.Narratiefupdate • Nov 07
MET: Revenue Will Advance On New Retirement Income And Employee Support Agreements
Analysts have slightly reduced their price target for MetLife from $93.33 to $93.00, reflecting minor adjustments to discount rate and profit margin assumptions. They maintain a positive outlook on revenue growth.Narratiefupdate • Oct 24
Digital Expansion And Employee Support Benefits Will Drive Outperformance Ahead
Analysts have modestly raised their price target for MetLife, increasing it from $93.00 to $93.33 per share. They cited slight improvements in projected revenue growth and profit margins as the reason for the adjustment.Narratiefupdate • Oct 09
International Demand And Digital Transformation Will Fuel Success
Analysts have raised their fair value estimate for MetLife from $91.86 to $93.00. This reflects slight adjustments to discount rates and growth assumptions.Narratiefupdate • Sep 04
International Demand And Digital Transformation Will Fuel Success
With no change in revenue growth forecasts or discount rate, MetLife’s fair value estimate remains steady at $91.86. What's in the News MetLife will redeem all outstanding shares of its 3.850% Fixed Rate Reset Non-Cumulative Preferred Stock, Series G, at $1,000 per share; dividends of $19.250 per share will be paid separately, and all further dividends cease post-redemption.Seeking Alpha • Feb 11
MetLife: Double-Digit EPS Growth With A Single-Digit P/E, Strong Chart
Summary MetLife, Inc. is rated a buy due to its solid value, above-market dividend yield, and favorable technical chart despite recent earnings misses. Insurance stocks, including MET, have lagged behind the Financials sector and S&P 500, with premium increases expected to slow as consumers react to rising costs. MET's 2025 outlook is positive, with analysts forecasting over 17% EPS growth and 5%-6% revenue growth, despite recent underperformance in certain segments. Key risks include lower stock prices, falling interest rates, and regulatory challenges, but MET's strong investment income and share buybacks are positive factors. Read the full article on Seeking AlphaSeeking Alpha • Nov 26
MetLife Upgraded To Buy As Financials And Insurance Show Further Upside Potential
Summary MetLife stock gets upgraded to a buy, from my prior hold rating, as indicators point to further share price potential in the financials sector, as well as the insurance subsector. Data points to future continued demand for annuities and life insurance, and MetLife has in Q3 achieved new organic customer growth in 2 key businesses. Although its dividend yield is not stellar vs. peers, it has a 10-year track record of proven dividend growth, something it has potential to continue. Even though it is trading at a 10-year high, it remains undervalued on P/E and EV/EBITDA vs. peers, so continues to present a buy opportunity. Read the full article on Seeking AlphaSeeking Alpha • Sep 23
MetLife: One Of The Best Life Insurance Stocks
Summary MetLife's strong financial performance, with a 17.5% increase in adjusted EPS and a 15.2% rise in book value, makes it an attractive investment. Despite comparable performance to Aflac, MetLife's lower valuation offers better value for shareholders. MetLife's growing dividend yield and robust share buyback program enhance shareholder value, with ample cash reserves supporting future buybacks. Risks include potential commercial real estate portfolio defaults and market volatility, but MetLife's strong fundamentals and attractive valuation make it a compelling choice. Read the full article on Seeking AlphaSeeking Alpha • Jul 09
Higher For Longer? Consider MetLife's Preferred Shares With A 6.6% Yield
Summary MetLife's preferred shares, particularly the Series A with floating dividends, offer potential for investors in a 'higher for longer' inflation and interest rate environment. MetLife's strong financial performance in Q1 2021, with net profit covering preferred dividends by less than 8%. Series A preferred shares have a minimum 4% floor for dividends, with potential for higher yields based on 3 month SOFR rate adjustments. Read the full article on Seeking AlphaSeeking Alpha • Jun 26
MetLife Looks Like An Undervalued Property In An Unpopular Neighborhood
Summary MetLife shares have outperformed peers, but life insurance stocks have not really been in favor given concerns about CRE losses and rate cuts. Higher rates have allowed MetLife to reprice its investment portfolio at higher rates and sell more spread products, and the benefits will last even as rates fall. There are understandable concerns about MetLife's CRE exposure (office in particular), as the insurer is overweight here, but losses will take years to materialize and can be absorbed. MetLife's focus on profitable core businesses like group life and health, pension risk transfer, and international markets should lead to steady growth and returns for investors. This is something of a contrarian call given weak sector sentiment, but MetLife's differentiated model and ability to out-earn its cost of equity should drive outperformance. Read the full article on Seeking AlphaRendement voor aandeelhouders
| MET | US Insurance | US Markt | |
|---|---|---|---|
| 7D | -4.1% | -0.8% | -2.1% |
| 1Y | 17.9% | 3.0% | 18.8% |
Rendement versus industrie: MET overtrof de US Insurance industrie, die het afgelopen jaar een rendement 3 % opleverde.
Rendement versus markt: MET presteerde slechter dan US Market, dat het afgelopen jaar een rendement van 18.8 % opleverde.
Prijsvolatiliteit
| MET volatility | |
|---|---|
| MET Average Weekly Movement | 3.3% |
| Insurance Industry Average Movement | 4.7% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.1% |
Stabiele aandelenkoers: MET heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend vergeleken met de US markt.
Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 3% ) van MET is het afgelopen jaar stabiel geweest.
Over het bedrijf
| Opgericht | Werknemers | CEO | Website |
|---|---|---|---|
| 1999 | 46,000 | Michel Khalaf | www.metlife.com |
MetLife, Inc., een financiële dienstverlener, biedt wereldwijd diensten aan op het gebied van verzekeringen, lijfrentes, employee benefits en vermogensbeheer. Het bedrijf is actief in zes segmenten: Group Benefits; Retirement and Income Solutions; Azië; Latijns-Amerika; Europa, het Midden-Oosten en Afrika; en MetLife Holdings. Het bedrijf biedt levensverzekeringen, tandverzekeringen, collectieve arbeidsongeschiktheidsverzekeringen op korte en lange termijn, betaald verlof voor gezins- en medische zorg, individuele arbeidsongeschiktheidsverzekeringen, ongevallen- en ziektekostenverzekeringen, zichtverzekeringen en huisdierverzekeringen, evenals prepaid juridische plannen; regelingen voor werkgevers die alleen administratieve diensten leveren; en algemene en aparte rekeningverzekeringen en synthetische contracten met gegarandeerde rente, evenals private financieringsovereenkomsten met variabele rente.
MetLife, Inc. Samenvatting
| MET fundamentele statistieken | |
|---|---|
| Marktkapitalisatie | US$60.44b |
| Inkomsten(TTM) | US$3.44b |
| Inkomsten(TTM) | US$79.40b |
17.3x
Koers/Winstverhouding0.7x
P/S-verhoudingIs MET overgewaardeerd?
Zie Reële waarde en waarderingsanalyseInkomsten en omzet
| MET resultatenrekening (TTM) | |
|---|---|
| Inkomsten | US$79.40b |
| Kosten van inkomsten | US$60.38b |
| Brutowinst | US$19.02b |
| Overige uitgaven | US$15.58b |
| Inkomsten | US$3.44b |
Laatst gerapporteerde inkomsten
Jun 30, 2026
Volgende inkomensdatum
n.v.t.
| Winst per aandeel (EPS) | 5.41 |
| Brutomarge | 23.95% |
| Nettowinstmarge | 4.33% |
| Schuld/Eigen Vermogen Verhouding | 179.9% |
Hoe presteerde MET op de lange termijn?
Bekijk historische prestaties en vergelijkingDividenden
2.5%
Huidig dividendrendement44%
UitbetalingsratioBetaalt MET een betrouwbaar dividend?
Zie MET dividendgeschiedenis en benchmarks| MetLife dividenddata | |
|---|---|
| Ex Dividend Datum | Aug 04 2026 |
| Betaaldatum dividend | Sep 08 2026 |
| Dagen tot Ex-dividend | 17 days |
| Dagen tot dividendbetaaldatum | 18 days |
Betaalt MET een betrouwbaar dividend?
Zie MET dividendgeschiedenis en benchmarksBedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/08/20 10:38 |
| Aandelenkoers aan het einde van de dag | 2026/08/20 00:00 |
| Inkomsten | 2026/06/30 |
| Jaarlijkse inkomsten | 2025/12/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysamodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina, we hebben ook handleidingen over hoe u onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
MetLife, Inc. wordt gevolgd door 32 analisten. 11 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| Jacob Kilstein | Argus Research Company |
| Jay Gelb | Barclays |
| Taylor Scott | Barclays |